Test Price
2,800 AED✅ Home Collection Available
FGFR3 Gene Crouzon Syndrome with Acanthosis Nigricans Genetic Test in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑Accredited Next‑Generation Sequencing (NGS), certified under ISO 9001:2015.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation with our DHA‑licensed Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
- Price: 2,800 AED – All‑inclusive of laboratory analysis, clinical report, and post‑test teleconsultation.
Test Overview & Methodology
The FGFR3 Genetic Test identifies pathogenic variants in the FGFR3 gene associated with Crouzon syndrome with acanthosis nigricans, enabling definitive molecular diagnosis and informed clinical management. This Next‑Generation Sequencing (NGS) assay covers the entire FGFR3 coding region, including splice sites and flanking intronic regions, ensuring comprehensive variant detection for craniosynostosis syndromes.
| Feature | Our NGS Test (ISO 9001:2015) | Standard Sanger Sequencing |
|---|---|---|
| Precision (Sensitivity) | 99.9% – covers entire coding region, deletions/duplications | ~95% – limited to single amplicons, miss larger CNVs |
| Methodology | Next‑Generation Sequencing (NGS) + bio‑informatics | Capillary electrophoresis, single‑gene sequencing |
| Turnaround Time | 3–4 Weeks (express possible) | 4–6 Weeks |
| Regulatory Compliance | DHA‑MOHAP NGS Standards, ISO 9001:2015, UAE PDPL | May lack ISO accreditation |
Physician Insight & Safety Protocols
“Accurate interpretation of FGFR3 variants requires integration of clinical phenotype, cranial imaging, and family pedigree analysis. A negative NGS result does not eliminate all craniosynostosis syndromes; careful correlation with physical findings and, if indicated, chromosomal microarray or whole‑exome sequencing should be considered. Always review results directly with your geneticist before altering any medical or surgical plans.”
– Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Medication & Clinical Safety Advisory
Do not discontinue prescribed medication or hormonal therapy without consulting your personal doctor. Genetic test results alone do not override existing treatment plans. Patients should continue all current medications and therapies until explicitly directed otherwise by their managing physician.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Individuals under 18 years without legal guardian consent; patients unable to provide a sufficient blood/DNA sample; those with active systemic infection at collection site that cannot be rescheduled.
- Exclusion: Prior allogeneic bone marrow transplantation may interfere with genetic analysis of blood DNA – a pre‑test buccal swab or fibroblast culture may be advised.
- ER Red Flags: If the patient (especially an infant) develops sudden intense headaches, projectile vomiting, downward gaze deviation (sunset sign), or rapid head enlargement, seek immediate emergency care – these can indicate raised intracranial pressure due to craniosynostosis.
Patient FAQ & Clinical Guidance
1. What does the FGFR3 NGS test detect in Crouzon syndrome with acanthosis nigricans?
Direct Answer: The FGFR3 NGS test identifies pathogenic DNA variants in the entire FGFR3 gene, confirming the specific mutation causing Crouzon syndrome with acanthosis nigricans. The assay detects single‑nucleotide variants, small insertions/deletions, and copy number changes across the coding region.
2. How should I prepare before giving blood for this genetic test?
Direct Answer: No fasting or medication adjustments are required; simply hydrate well and provide your detailed personal/family medical history for accurate variant interpretation. A standard peripheral blood draw is used for DNA extraction.
3. My child’s result shows a “variant of uncertain significance” – what now?
Direct Answer: A variant of uncertain significance requires clinical correlation and possibly testing of both parents (segregation analysis) to clarify whether it is disease‑causing or benign. Your geneticist may also recommend functional studies or re‑analysis as new evidence emerges.
4. Is home sample collection available for this genetic test?
Direct Answer: Yes, our VIP Mobile Phlebotomy service collects peripheral blood samples at your home or hotel between 8 AM and 11 PM daily, using temperature‑controlled cold‑chain logistics to ensure sample integrity. You can schedule by calling or messaging +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Security: All patient genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genomic information is encrypted, access‑controlled, and never shared with third parties without explicit consent.
Clinical Safety & Consent: Genetic counselling and informed consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring every patient understands the scope, benefits, and limitations of NGS testing before proceeding.
Clinical & Logistical Metadata
| Test Name | FGFR3 Gene Crouzon Syndrome with Acanthosis Nigricans Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (3–5 mL in EDTA tube) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Whole FGFR3 Coding Region Analysis |
| ICD-10-CM Code | Q87.0 (Congenital malformation syndromes predominantly affecting facial appearance), L83 (Acanthosis nigricans) |
| LOINC Code | 21636-6 (FGFR3 gene mutation analysis) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
ISO 9001:2015 Certified – Certificate INT/EGQ/2509DA/3139.
Support: +971 54 548 8731 (WhatsApp, 8 AM–11 PM).
Medical Disclaimer: This page is for educational purposes and does not replace professional medical advice. Always seek the guidance of a DHA‑licensed physician.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians